These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 32875742)

  • 1. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
    Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
    Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
    McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
    Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
    Li X; Ding X; Li W; Chen J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
    J Hepatol; 2024 Aug; 81(2):258-264. PubMed ID: 38570034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients.
    Lin PT; Teng W; Jeng WJ; Lin CY; Lin SM; Sheen IS
    Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):213-219. PubMed ID: 33177386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
    Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
    Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
    Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
    Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
    Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
    Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study.
    Zhang Y; Fan W; Wang Y; Huang G; Li J
    Cancer Control; 2019; 26(1):1073274819872216. PubMed ID: 31466465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.